Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 2,145 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total value of $39,596.70. Following the sale, the chief financial officer owned 216,637 shares of the company’s stock, valued at $3,999,119.02. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kyle Piskel also recently made the following trade(s):

• On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total value of $77,220.00.
• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.50, for a total value of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total value of $3,343.90.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT traded down $0.70 on Friday, hitting $15.77. 4,139,315 shares of the company were exchanged, compared to its average volume of 1,811,910. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76. The firm has a market capitalization of $2.41 billion, a P/E ratio of -39.42 and a beta of 2.18. The company’s 50 day moving average price is $17.03 and its 200-day moving average price is $15.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 48.73%. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the firm posted ($0.23) earnings per share. The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. As a group, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Guggenheim increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday. BTIG Research upped their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. Finally, JPMorgan Chase & Co. increased their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently added to or reduced their stakes in the business. Sound Income Strategies LLC bought a new position in shares of Adaptive Biotechnologies during the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. raised its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after buying an additional 3,371 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after acquiring an additional 1,532 shares in the last quarter. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.